Daratumumab(945721-28-8)
- Name: Daratumumab
- Synonyms:Daratumumab;Daratumumab - 20mg/ml in water;Daratumumab 21.7mg/ml;Daratumumab USP/EP/BP;Research Grade Daratumumab(DHD80801);Anti-Human CD38, Human Antibody,myeloma,inhibit,tumor,antibody,cell,adhesion,cytotoxicity,Inhibitor,Daratumumab;Research Grade Daratumumab;Daratumumab - 20mg/ml in buffer
- Molecular Formula:
- Molecular Weight:0
- CAS Registry Number:945721-28-8
- EINECS:
- Melting Point:
- Water Solubility:
Other Product
- 945611-41-6/1H-Imidazolium, 3-butyl-1,2-dimethyl-, acetate (1:1)
- 945623-45-0/N-ethyl-3-(propan-2-yl)aniline
- 945624-15-7/2-Pyridinamine, 5-chloro-3-(4-chlorophenyl)-
- 945627-45-2/Ethanethioic acid, S-[[5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]phenyl]methyl] ester
- 945628-51-3/2,4(1H,3H)-Pyrimidinedione, 1-[2,5-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-3-O-[[bis(1-methylethyl)amino](2-cyanoethoxy)phosphino]-6-deoxy-α-L-mannofuranosyl]-
- 945628-57-9/Benzamide, N-[1-[2,5-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-3-O-[[bis(1-methylethyl)amino](2-cyanoethoxy)phosphino]-6-deoxy-α-L-mannofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]-
- 945628-63-7/Propanamide, N-[9-[2,5-anhydro-6-deoxy-4-C-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-α-L-mannofuranosyl]-6,9-dihydro-6-oxo-1H-purin-2-yl]-2-methyl-
- 945628-64-8/Propanamide, N-[9-[2,5-anhydro-6-deoxy-4-C-(hydroxymethyl)-α-L-mannofuranosyl]-6,9-dihydro-6-oxo-1H-purin-2-yl]-2-methyl-
- 945632-87-1/2-Naphthaleneethanol, β-amino-1,2,3,4-tetrahydro-6-octyl-
- 94564-81-5/2-(Aminomethyl)-1,3-benzenediol
- 945651-03-6/(4S)-4-amino-5-(benzyloxy)-5-oxopentanoic acid hydrochloride
- 945652-32-4/Carbamic acid, N-[2-(phenylmethoxy)cyclohexyl]-, 1,1-dimethylethyl ester
- 945653-13-4/Iron, [2,6-bis(1,1-dimethylethyl)-N-[2-[[2-(diphenylphosphino-κP)ethyl]imino-κN]-1(2H)-acenaphthylenylidene]benzenamine-κN]dichloro-
- 945656-77-9/4H,6H-Indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinium, 2-(2,6-difluorophenyl)-5a,10b-dihydro-, chloride (1:1), (5aR,10bS)-
- 945668-95-1/Butanedioic acid, 2,3-bis(benzoyloxy)-, (2S,3S)-, compd. with (3aS,7aS)-octahydro-6-(2-phenylethyl)-1H-pyrrolo[2,3-c]pyridine (1:1)
- 945681-44-7/Cyclohexanol, 1-methyl-4-(1-methylethenyl)-2-(4-morpholinyl)-, (1S,2S,4S)-
- 945681-45-8/Cyclohexanol, 2-methyl-5-(1-methylethenyl)-2-(4-morpholinyl)-, (1R,2R,5S)-
- 945-68-2/2-Amino-5-Bromo-3-nitropyridine
- 945715-44-6/Diethylmethylammonium methanesulfonate
- 945721-28-8/Daratumumab
- 945721-87-9/GSK726701A
- 945723-63-7/10-Oxa-2,5,8-triazadodecanoic acid, 5,11,11-trimethyl-9-oxo-, 1,1-dimethylethyl ester
- 945723-71-7/Pyridine, 2-iodo-4-phenyl-
- 945732-42-3/1-Allyl-3-ethylimidazolium tetrafluoroborate
- 945739-26-4/1-tosyl-3-(trifluoromethyl)-1H-pyrrole
- 945739-76-4/Glycine, N-[[1-cyano-4-hydroxy-6-(4-methoxyphenoxy)-3-isoquinolinyl]carbonyl]-
- 945741-97-9/2-dimethylamino-benzooxazol-5-ol
- 945745-52-8/Isopropyl 4-isopropoxy-3-methoxybenzoate
- 945746-56-5/Benzamide, 2,6-dichloro-N-[3-[[4-(2,4-dichlorophenyl)-2-pyrimidinyl]amino]propyl]-
- 945746-57-6/Benzamide, 2,6-dichloro-N-[3-[[4-[4-(dimethylamino)phenyl]-2-pyrimidinyl]amino]propyl]-